



## **Ningetinib Tosylate**

Catalog No: tcsc0027426

Available Sizes
Size: 5mg
Size: 10mg
Size: 25mg
Size: 50mg
Size: 100mg
Specifications Specifications
CAS No: 1394820-77-9
<b>Formula:</b> $C_{38}^{H}_{37}^{FN}_{4}^{O}_{8}^{S}$
Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK
Target: c-Met/HGFR;VEGFR;TAM Receptor
Purity / Grade: >98%
Solubility: DMSO: 8.25 mg/mL (11.32 mM; Need ultrasonic and warming)
Observed Molecular Weight: 728.79





## **Product Description**

Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (**TKI**) with **IC**<sub>50</sub>s of 6.7, 1.9 and c-Met, **VEGFR2** and **AxI**, respectively.

In Vitro: Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC<sub>50</sub>s of 6.7, 1.9 and 50 values of 8.6 and 6.3 nM, respectively<sup>[1]</sup>.

*In Vivo:* When single dosed orally (3 mg/kg) to U87MG tumor-bearing nude mice, Ningetinib Tosylate (CT053PTSA) potently inhibits the phosphorylation of c-Met and its downstream signaling kinases AKT and ERK1/2 for up to 6 hours in tumor tissues. In orthotopic U87MG human glioblastoma xenograft model, Ningetinib Tosylate prolongs the median survival time (MST) and yields significant increase in life-span value (ILS=32%, p=0.003) at an oral dose of 20 mg/kg/day (dosed 21 days) versus the vehicle-treated group<sup>[1]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!